Olympus Corporation
Stock Price Chart
2026/06/15 UpdatedPrice Trend
2026/06/15 UpdatedPrice & Trading Details
2026/06/15 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/11 | ¥9.20 | ¥22.45 | +143.9% |
| 2026/02/12 | ¥18.96 | ¥12.87 | -32.1% |
| 2025/11/06 | ¥16.21 | ¥18.03 | +11.2% |
| 2025/08/07 | ¥15.82 | ¥7.97 | -49.6% |
Shareholder Composition
Updated 2026/06/05Top Mutual Funds / ETFs
Updated 2026/06/05Major Holders
Updated 2026/06/05| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Artisan Partners Funds Inc.-Artisan International Value Fund
|
41.0M | +1.00% | |
|
Dodge & Cox Funds-Dodge & Cox International Stock Fund
|
21.4M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
15.5M | -1.10% | |
|
MFS Series Trust XVII-MFS International Equity Fund
|
13.5M | -37.22% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
10.0M | +0.36% | |
|
Bridge Builder Trust-Bridge Builder International Equity Fund
|
8.8M | +12.80% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
19.8K | +54.09% |
Dividend History 4Years Growth
Updated 2026/06/14| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥30 | +50.0% |
| 2025 | ¥20 | +11.1% |
| 2024 | ¥18 | +12.5% |
| 2023 | ¥16 | +14.3% |
| 2022 | ¥14 | - |
Financial Performance
2026/06/14 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥750,123M | ¥881,923M | ¥925,752M | ¥997,332M |
| Gross Profit | ¥506,700M | ¥596,849M | ¥618,432M | ¥683,697M |
| Operating Income | ¥144,696M | ¥186,118M | ¥51,745M | ¥161,996M |
| Pretax Income | ¥147,539M | ¥190,469M | ¥53,907M | ¥165,911M |
| Net Income | ¥115,742M | ¥143,432M | ¥242,566M | ¥117,855M |
| EPS | ¥90.17 | ¥113.08 | ¥199.44 | ¥102.80 |
| Operating Margin | 19.29% | 21.10% | 5.59% | 16.24% |
| Balance Sheet | ||||
| Total Assets | ¥1,357,999M | ¥1,508,701M | ¥1,534,216M | ¥1,432,826M |
| Total Equity | ¥510,168M | ¥640,085M | ¥757,186M | ¥751,733M |
| Total Liabilities | ¥847,831M | ¥868,616M | ¥777,030M | ¥681,093M |
| Cash | ¥302,572M | ¥169,329M | ¥340,933M | ¥252,532M |
| Interest-bearing Debt | ¥386,127M | ¥340,057M | ¥299,616M | ¥229,102M |
| Equity Ratio | 37.57% | 42.43% | 49.35% | 52.47% |
| D/E Ratio | 0.76 | 0.53 | 0.40 | 0.30 |
| Cash Flow | ||||
| Operating CF | ¥169,729M | ¥98,490M | ¥42,365M | ¥190,463M |
| Investing CF | -¥71,016M | -¥58,414M | ¥359,992M | -¥65,469M |
| Financing CF | -¥40,667M | -¥143,178M | -¥276,010M | -¥211,542M |
| Free CF | ¥107,958M | ¥27,867M | -¥22,259M | ¥125,254M |
| Efficiency | ||||
| ROE | 22.69% | 22.41% | 32.04% | 15.68% |
| ROA | 8.52% | 9.51% | 15.81% | 8.23% |
Latest IR Information
-
【Olympus】Completion of BioProtect Subsidiary Acquisition ｜ June 2026
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. The acquisition price was approximately 43.3 billion yen, and its impact on future performance is being examined.
Read more -
【Olympus】 Completion of Endoscope-Related Treatment Business Acquisition | May 2026
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing the establishment of a wholly owned subsidiary. This aims to expand the endoscope-related business portfolio and strengthen cancer treatment solutions.
Read more -
【Olympus】 Completion of Share Buyback and Cancellation ｜ May 2026
Olympus completed the purchase of 38,948,300 shares of treasury stock (equivalent to approximately 6 billion yen) on May 12, 2026, resolution was made to cancel 29,948,300 shares of treasury stock (2.69% of issued shares) on the same day, scheduled for...
Read more -
Resolution on Share Buyback and Cancellation｜May 2026
Olympus aims to enhance shareholder returns and capital efficiency by acquiring up to 46 million shares for a total of 6 billion yen, with plans to cancel these shares in April 2027.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥1,882
Rating Score: 2.43 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
